Trial
NCT03565406
A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
NYU Langone Health
Collaborators
—
Condition
Melanoma
Intervention
Mocetinostat Induction Phase + Ipilimumab + Nivolumab
Why stopped
recruiting or enrolling participants has halted prematurely and will not resume; participants are no longer being examined or treated
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-05-21